Abstract
Recent failures to detect efficacy in clinical trials investigating pharmacological treatments for schizophrenia raise concerns regarding the potential contribution of methodological shortcomings to this research. This review provides an examination of two key methodological issues currently suspected of playing a role in hampering schizophrenia drug development; 1) limitations on the translational utility of preclinical development models, and 2) methodological challenges posed by increased placebo effects. Recommendations for strategies to address these methodological issues are addressed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 591-604 |
| Number of pages | 14 |
| Journal | Expert Review of Clinical Pharmacology |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2 2016 |
| Externally published | Yes |
Keywords
- clinical trials
- drug development
- methodological issues
- pharmacology
- placebo effect
- preclinical
- schizophrenia
- treatment efficacy
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)
- Pharmacology (medical)